Aclaris therapeutics announces publication of preclinical research of zunsemetinib in pancreatic cancer in science translational medicine

Wayne, pa., dec. 03, 2021 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the publication of preclinical research of zunsemetinib in pancreatic cancer in the peer-reviewed journal science translational medicine, on december 1, 2021.
ACRS Ratings Summary
ACRS Quant Ranking